Clinical trial
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor…
NCT00089661 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00089661 |
|---|---|
| Title | AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Low Bone Mineral Density, Osteopenia |
| Intervention type | Drug |
| Interventions | Placebo, AMG 162 / Denosumab |
| Enrollment | 252 |
| Start date | Oct 1, 2004 |
| Primary completion | May 11, 2007 |
| Completion | May 27, 2009 |
| First posted | Aug 11, 2004 |
| Last update posted | Oct 17, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: